Economic assessment of NGS testing workflow for NSCLC in a healthcare setting

• Published in: Heliyon Vol. 10; no. 7; p. e29272
• Main Authors: Seminati, Davide, L'Imperio, Vincenzo, Casati, Gabriele, Ceku, Joranda, Pilla, Daniela, Scalia, Carla Rossana, Gragnano, Gianluca, Pepe, Francesco, Pisapia, Pasquale, Sala, Luca, Cortinovis, Diego Luigi, Bono, Francesca, Malapelle, Umberto, Troncone, Giancarlo, Novello, Silvia, Pagni, Fabio
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 15.04.2024; Elsevier
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e29272

The molecular diagnostic and therapeutic pathway of Non-Small Cell Lung Cancer (NSCLC) stands as a successful example of precision medicine. The scarcity of material and the increasing number of biomarkers to be tested have prompted the routine application of next-generation-sequencing (NGS) techniques. Despite its undeniable advantages, NGS involves high costs that may impede its broad adoption in laboratories. This study aims to assess the detailed costs linked to the integration of NGS diagnostics in NSCLC to comprehend their financial impact. The retrospective analysis encompasses 210 cases of early and advanced stages NSCLC, analyzed with NGS and collected at the IRCCS San Gerardo dei Tintori Foundation (Monza, Italy). Molecular analyses were conducted on FFPE samples, with an hotspot panel capable of detecting DNA and RNA variants in 50 clinically relevant genes. The economic analysis employed a full-cost approach, encompassing direct and indirect costs, overheads, VAT (Value Added Tax). We estimate a comprehensive cost for each sample of €1048.32. This cost represents a crucial investment in terms of NSCLC patients survival, despite constituting only around 1% of the expenses incurred in their molecular diagnostic and therapeutic pathway. The cost comparison between NGS test and the notably higher therapeutic costs highlights that the diagnostic phase is not the limiting economic factor. Developing NGS facilities structured in pathology networks may ensure appropriate technical expertise and efficient workflows. •Cost Assessment: DNA/RNA NGS diagnostics in NSCLC - €1048.32 per sample.•Financial Impact: Crucial investment, 1% of overall molecular expenses.•Survival Investment: Enhances NSCLC patient survival rates.•Economic Insight: Diagnostic phase is not the limiting factor.•Optimization Recommendation: Develop NGS facilities in structured networks.